Literature DB >> 18573503

Validation of a rabbit model of neuropathy induced by immunization with gangliosides.

A L Moyano1, R Comín, R D Lardone, M E Alaniz, R Theaux, F J Irazoqui, G A Nores.   

Abstract

The induction of neurological signs by immunization of rabbits with gangliosides has been a controversial topic for many years. Recently, Yuki et al. [N. Yuki, M. Yamada, M. Koga, M. Odaka, K. Susuki, Y. Tagawa, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001;49:712-720.] described an immunization protocol, including keyhole lympet hemocyanin in addition to ganglioside that induced a neurological disease resembling human Guillain-Barré syndrome. We employed this protocol in our laboratory and succeeded in reproducing the disease. Five different experiments were performed during a period of two years by different operators, using different batches of drugs, in a total of 26 rabbits. Despite minor variations in onset time and severity of the induced disease, the model proved to be reproducible. Both gangliosides and keyhole limpet hemocyanin are required for induction of disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573503     DOI: 10.1016/j.jns.2008.05.006

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

Review 1.  Novel pathomechanisms in inflammatory neuropathies.

Authors:  David Schafflick; Bernd C Kieseier; Heinz Wiendl; Gerd Meyer Zu Horste
Journal:  J Neuroinflammation       Date:  2017-11-28       Impact factor: 8.322

2.  Case Report: Delayed Guillain-Barré syndrome following trauma: A case series and manage considerations.

Authors:  Yiliu Zhang; Chuxin Huang; Wei Lu; Qing Hu
Journal:  Front Surg       Date:  2022-08-25

Review 3.  Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes?

Authors:  Nicola Principi; Susanna Esposito
Journal:  Front Public Health       Date:  2020-07-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.